Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultralife (ULBI) Common Equity (2016 - 2025)

Historic Common Equity for Ultralife (ULBI) over the last 15 years, with Q3 2025 value amounting to $137.4 million.

  • Ultralife's Common Equity rose 208.28% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year increase of 208.28%. This contributed to the annual value of $134.2 million for FY2024, which is 698.41% up from last year.
  • Latest data reveals that Ultralife reported Common Equity of $137.4 million as of Q3 2025, which was up 208.28% from $138.6 million recorded in Q2 2025.
  • Ultralife's Common Equity's 5-year high stood at $138.6 million during Q2 2025, with a 5-year trough of $116.4 million in Q1 2023.
  • Moreover, its 4-year median value for Common Equity was $127.2 million (2023), whereas its average is $127.3 million.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 1142.26% in 2024, then surged by 208.28% in 2025.
  • Over the past 4 years, Ultralife's Common Equity (Quarter) stood at $118.5 million in 2021, then increased by 5.8% to $125.4 million in 2023, then increased by 6.98% to $134.2 million in 2024, then grew by 2.42% to $137.4 million in 2025.
  • Its last three reported values are $137.4 million in Q3 2025, $138.6 million for Q2 2025, and $136.6 million during Q1 2025.